Company profile
Latigo Biotherapeutics, Inc.
NASDAQ:LTGOBiotechnology: Pharmaceutical Preparations
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06049095 | phase1 | active_not_recruiting | 2023-10-17 | 2026-09-01 | Latigo Biotherapeutics | A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants |
| NCT06554574 | phase1 | completed | 2024-09-03 | 2025-06-16 | Latigo Biotherapeutics | A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants |
| NCT07341152 | phase1 | completed | 2025-10-06 | 2025-11-17 | Latigo Biotherapeutics | A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants |
| NCT07102459 | phase2 | completed | 2025-07-24 | 2026-01-07 | Latigo Biotherapeutics | An Efficacy and Safety Study of LTG-001 Following Abdominoplasty |
| NCT06972212 | — | completed | 2025-06-04 | 2025-06-28 | Latigo Biotherapeutics | Pharmacodynamic Study of 100mg Suzegtrigine vs Placebo in Healthy Male Adults |
FDA applications (0)
No records yet.